- Home
- MRNA vs SNN Comparison
MRNA vs SNN Comparison
Compare MRNA & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- SNN
- Stock Information
- Founded
- MRNA 2010
- SNN 1856
- Country
- MRNA United States
- SNN United Kingdom
- Employees
- MRNA N/A
- SNN N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- SNN Industrial Specialties
- Sector
- MRNA Health Care
- SNN Health Care
- Exchange
- MRNA Nasdaq
- SNN Nasdaq
- Market Cap
- MRNA 10.6B
- SNN 12.7B
- IPO Year
- MRNA 2018
- SNN 1999
- Fundamental
- Price
- MRNA $25.90
- SNN $28.83
- Analyst Decision
- MRNA Hold
- SNN Hold
- Analyst Count
- MRNA 19
- SNN 3
- Target Price
- MRNA $48.13
- SNN $27.50
- AVG Volume (30 Days)
- MRNA 10.5M
- SNN 780.9K
- Earning Date
- MRNA 07-31-2025
- SNN 07-31-2025
- Dividend Yield
- MRNA N/A
- SNN 2.58%
- EPS Growth
- MRNA N/A
- SNN 56.15
- EPS
- MRNA N/A
- SNN 0.47
- Revenue
- MRNA $3,177,000,000.00
- SNN $5,810,000,000.00
- Revenue This Year
- MRNA N/A
- SNN $6.87
- Revenue Next Year
- MRNA $9.87
- SNN $5.19
- P/E Ratio
- MRNA N/A
- SNN $30.62
- Revenue Growth
- MRNA N/A
- SNN 4.70
- 52 Week Low
- MRNA $23.15
- SNN $23.69
- 52 Week High
- MRNA $138.07
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- MRNA 46.10
- SNN 49.61
- Support Level
- MRNA $25.06
- SNN $28.40
- Resistance Level
- MRNA $28.72
- SNN $30.38
- Average True Range (ATR)
- MRNA 1.18
- SNN 0.36
- MACD
- MRNA -0.18
- SNN -0.17
- Stochastic Oscillator
- MRNA 20.34
- SNN 30.00
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.